Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Murat BozdagUniversità Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.ORCID 0000-0002-5010-0355
Nabil MrowehUniversità Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.
Alessia RaucciDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.
Andrea AngeliUniversità Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.ORCID 0000-0002-1470-7192
Silvia PeppicelliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50134, Italy.
Alessio BiagioniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50134, Italy.
Lido CaloriniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50134, Italy.
Daniela TrisciuoglioInstitute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), Rome 00185, Italy.
Rino RagnoDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.ORCID 0000-0001-5399-975X
Roberta AstolfiDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.ORCID 0009-0002-0199-7730
Lidia GiulianiDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.
Clemens ZwergelDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.ORCID 0000-0002-3097-0003
Sergio ValenteDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.ORCID 0000-0002-2241-607X
Elena AndreucciDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50134, Italy.
Fabrizio CartaUniversità Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.ORCID 0000-0002-1141-6146
Antonello MaiDepartment of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.ORCID 0000-0001-9176-2382
Claudiu T SupuranUniversità Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.ORCID 0000-0003-4262-0323
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells. · full record | OpenQuestion